Europe Autoimmune Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Europe Autoimmune Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The Europe Autoimmune Disease Diagnostics Market size is estimated at USD 1.38 billion in 2024, and is expected to reach USD 1.82 billion by 2029, growing at a CAGR of 5.69% during the forecast period (2024-2029).

The major factors driving the market are the increasing prevalence, along with the rising public awareness, technological advancements, and improved laboratory automation.

European countries are being confronted with an increase in the occurrence of the most autoimmune immune disorders. The prevalence rate of multiple sclerosis in Europe is estimated at 83 out of 100,000. Moreover, multiple sclerosis is more common among women than men. In addition, two million people are affected by rheumatoid arthritis and nearly 2-3% of the population is estimated to be affected by psoriasis, which is one of the most common forms of autoimmune diseases. Owing to the aforementioned conditions, early diagnosis and onset of treatment can make a significant difference in preventing permanent damage and disability. Results of autoimmune disease diagnostic tests can confirm a disorder, estimate disease severity, aid in assessing prognosis. They are also useful to follow disease activity.

The increasing awareness of auto-immune diseases, through programs of research, education, support, and advocacy is a key factor augmenting the usage rates. The European Commission is taking several steps to increase awareness among the public regarding the risk factors in developing autoimmune diseases. Thus, as symptoms occur, they can seek diagnosis and begin a treatment regimen.

Europe Autoimmune Disease Diagnostics Market Trends

Rheumatoid Arthritis is Expected to Dominate the Systemic Autoimmune Disease Segment in the Coming Future

Rheumatoid arthritis is a chronic, progressive, and inflammatory autoimmune disease associated with HLA-DR4 and HLA-DR1 serotypes, characterized by persistent inflammation of the synovium that leads to the destruction of joints. The availability of treatment options, such as biologics, increasing awareness about rheumatoid arthritis, and the presence of reimbursement schemes across many countries are driving the growth of the segment. Rheumatoid arthritis (RA) is more prevalent in females. For instance, the United Kingdom has a prevalence rate of 1.2% in females and 0.4% in males.

Increasing incidence of autoimmune diseases, off-label prescription of NSAIDs, and other pain management drugs are expected to increase the demand for RA diagnosis. In addition, extensive focus on the high specificity and sensitivity of RA kits from kit manufacturers, and favorable regulatory guidelines for rapid RA diagnostic kits are expected to fuel the market growth.

Europe Autoimmune Disease Diagnostics Industry Overview

The European autoimmune disease diagnostics market is moderately competitive in nature. Some of the well-known players in the market are Abbott Laboratories, Biomérieux, Bio-rad Laboratories, F. Hoffmann-la Roche, and Thermo Fisher Scientific Inc. However, there are some new companies that are focusing on market penetration, owing to the growing market for autoimmune disease diagnostics in Europe.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support